Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.
about
New Strategies for the Treatment of Solid Tumors with CAR-T CellsChimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor ImmunityN-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3.Enhancing adoptive T cell immunotherapy with microRNA therapeutics.A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cellsSpotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.Engineered T cells: the promise and challenges of cancer immunotherapy.Tumor-targeting domains for chimeric antigen receptor T cells.Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.Therapeutic Antibodies against Intracellular Tumor AntigensPractical considerations for chimeric antigen receptor design and delivery.Treating hematological malignancies with cell therapy: where are we now?TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity.Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
P2860
Q26748500-EBA5C50E-DF9D-43F9-9906-3EB7A46F7AF4Q33700795-2B1F30D8-5C9E-4CA9-937D-F8886FAA7049Q35881238-11C96957-EE86-4D7E-B383-CB48F794400FQ36444198-C4948399-3AF7-4607-8FA9-247C5E2B2CA9Q36889204-018B13A5-A2D6-4FB0-B702-79C06E8F79FFQ36943923-AEC76846-E874-43A9-BCEF-0C813A323026Q38766349-3FBE4EDE-CD5E-44A5-8788-D5B7B31FFCC4Q38786626-D93BE988-5DE5-42D7-BD1F-5C4CF55C9169Q38828829-9BE1856C-EBA4-441C-BEA4-C669412AC840Q39045535-4EBA1965-8155-4B82-889C-8E73273347A9Q40973052-B2E2D1A1-248D-46DF-ABDF-B2ECA61A4038Q41462883-A76CE90D-9A8F-470F-922D-0BA6B01FC9FBQ45868559-173731F6-2F23-4C65-A4A8-0CCC1649155BQ48640926-238652C5-A621-4DB8-8E14-2175D5E3CDC7Q52691571-984EC7AF-1476-4733-AEEB-1253936391F6Q52804817-9A253D16-2162-4EAE-8F89-3721ABAE17B5Q53705286-B0CE2D57-95E3-46F3-8D2E-213A73F6817AQ56594845-FEEA1D09-4E14-4065-A83C-3688A539DE53
P2860
Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Affinity maturation of T-cell ...... nhances therapeutic potential.
@ast
Affinity maturation of T-cell ...... nhances therapeutic potential.
@en
type
label
Affinity maturation of T-cell ...... nhances therapeutic potential.
@ast
Affinity maturation of T-cell ...... nhances therapeutic potential.
@en
prefLabel
Affinity maturation of T-cell ...... nhances therapeutic potential.
@ast
Affinity maturation of T-cell ...... nhances therapeutic potential.
@en
P2093
P2860
P356
P1433
P1476
Affinity maturation of T-cell ...... nhances therapeutic potential.
@en
P2093
D V Tassev
N-K V Cheung
R J O'Reilly
P2860
P2888
P304
P356
10.1038/LEU.2015.125
P50
P577
2015-05-19T00:00:00Z
P6179
1004701537